{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:27:15Z","timestamp":1788474435672,"version":"build-2803163510"},"reference-count":62,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Host genetic factors significantly influence susceptibility to SARS-CoV-2 infection and COVID-19 severity. Among these genetic factors are single-nucleotide variants (SNVs). IFNAR2 and IFNAR1 genes have been associated with severe COVID-19 in populations from the United Kingdom, Africa, and Latin America. IFNAR1 and IFNAR2 are subunits forming the type I interferon receptor (IFNAR). SNVs in the IFNAR genes impact protein function, affecting antiviral response and disease phenotypes. This systematic review aimed to describe IFNAR1 and IFNAR2 variants associated with COVID-19 susceptibility and severity. Accordingly, the current review focused on IFNAR1 and IFNAR2 studies published between January 2021 and February 2023, utilizing the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) protocol. The electronic search was conducted in PubMed databases using Boolean operators and inclusion and exclusion criteria. Of the 170 literature pieces, 11 studies were included. We include case reports of rare SNVs, defined by minor allele frequency (MAF) &lt; 1%, and genome-wide associated studies (GWAS). Variants in IFNAR1 and IFNAR2 could potentially be new targets for therapies that limit the infection and the resulting inflammation by SARS-CoV-2 infection.<\/jats:p>","DOI":"10.3390\/pathogens12111320","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T01:37:09Z","timestamp":1699234629000},"page":"1320","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Participation of Single-Nucleotide Variants in IFNAR1 and IFNAR2 in the Immune Response against SARS-CoV-2 Infection: A Systematic Review"],"prefix":"10.3390","volume":"12","author":[{"given":"Mar\u00eda Fernanda","family":"L\u00f3pez-Bielma","sequence":"first","affiliation":[{"name":"HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cos\u00edo Villegas, Mexico City 14080, Mexico"},{"name":"Secci\u00f3n de Posgrado e Investigaci\u00f3n, Escuela Superior de Medicina, Instituto Polit\u00e9cnico Nacional, Mexico City 11340, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6877-8124","authenticated-orcid":false,"given":"Ramc\u00e9s","family":"Falf\u00e1n-Valencia","sequence":"additional","affiliation":[{"name":"HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cos\u00edo Villegas, Mexico City 14080, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7104","authenticated-orcid":false,"given":"Edgar","family":"Abarca-Rojano","sequence":"additional","affiliation":[{"name":"Secci\u00f3n de Posgrado e Investigaci\u00f3n, Escuela Superior de Medicina, Instituto Polit\u00e9cnico Nacional, Mexico City 11340, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6876-1012","authenticated-orcid":false,"given":"Gloria","family":"P\u00e9rez-Rubio","sequence":"additional","affiliation":[{"name":"HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cos\u00edo Villegas, Mexico City 14080, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1177\/1352458516667564","article-title":"Decreased soluble IFN-\u03b2 receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker","volume":"23","author":"Bada","year":"2017","journal-title":"Mult. Scler. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e20220028","DOI":"10.1084\/jem.20220028","article-title":"A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes","volume":"219","author":"Bastard","year":"2022","journal-title":"J. Exp. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Murphy, K., Travers, P., and Walport, M. (2008). Janeway\u2019s Immunobiology, Garland Science.","DOI":"10.1007\/978-3-8274-2219-4"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/jmv.27317","article-title":"The role of type I interferon in the treatment of COVID-19","volume":"94","author":"Sodeifian","year":"2022","journal-title":"J. Med Virol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.tig.2020.08.017","article-title":"Genetic Lesions of Type I Interferon Signalling in Human Antiviral Immunity","volume":"37","author":"Duncan","year":"2021","journal-title":"Trends Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.medj.2020.12.001","article-title":"Life-Threatening COVID-19: Defective Interferons Unleash Excessive Inflammation","volume":"1","author":"Zhang","year":"2020","journal-title":"Med"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1084\/jem.20182295","article-title":"Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines","volume":"216","author":"Hernandez","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9148","DOI":"10.1073\/pnas.0602800103","article-title":"Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence","volume":"103","author":"Frodsham","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3389\/fgene.2020.00937","article-title":"IFNAR2 Deficiency Causing Dysregulation of NK Cell Functions and Presenting With Hemophagocytic Lymphohistiocytosis","volume":"11","author":"Passarelli","year":"2020","journal-title":"Front. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.coviro.2021.11.002","article-title":"Host cell-intrinsic innate immune recognition of SARS-CoV-2","volume":"52","author":"Diamond","year":"2022","journal-title":"Curr. Opin. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.chom.2021.05.004","article-title":"Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19","volume":"29","author":"Lowery","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"902956","DOI":"10.3389\/fimmu.2022.902956","article-title":"Individual and Synergistic Anti-Coronavirus Activities of SOCS1\/3 Antagonist and Interferon \u03b11 Peptides","volume":"13","author":"Ahmed","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1126\/science.abm8108","article-title":"The Immunology and Immunopathology of COVID-19","volume":"375","author":"Merad","year":"2022","journal-title":"Science"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"622176","DOI":"10.3389\/fimmu.2021.622176","article-title":"Genetics Insight for COVID-19 Susceptibility and Severity: A Review","volume":"12","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.3389\/fimmu.2020.01606","article-title":"Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19","volume":"11","author":"Freytag","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.32607\/20758251-2012-4-3-59-71","article-title":"A Polygenic Approach to the Study of Polygenic Diseases","volume":"4","author":"Lvovs","year":"2012","journal-title":"Acta Naturae"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"The Severe COVID-19 GWAS Group (2020). Genome Association Study of Severe COVID-19 with Respiratory Failure. N. Engl. J. Med., 383, 1522\u20131534.","DOI":"10.1056\/NEJMc2025747"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/ebn.6.2.36","article-title":"Evaluation of qualitative research studies","volume":"6","author":"Russell","year":"2003","journal-title":"\u00c9vid. Based Nurs."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/XEB.0000000000000055","article-title":"Summarizing systematic reviews","volume":"13","author":"Aromataris","year":"2015","journal-title":"Int. J. Evid. Based Heal."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.midw.2005.05.004","article-title":"Appraising the quality of qualitative research","volume":"22","author":"Walsh","year":"2006","journal-title":"Midwifery"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41586-020-03065-y","article-title":"Genetic mechanisms of critical illness in COVID-19","volume":"591","author":"Clohisey","year":"2021","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41588-021-01006-7","article-title":"Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease","volume":"54","author":"Horowitz","year":"2022","journal-title":"Nat. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Dieter, C., Brondani, L.d.A., Lemos, N.E., Schaeffer, A.F., Zanotto, C., Ramos, D.T., Girardi, E., Pellenz, F.M., Camargo, J.L., and Moresco, K.S. (2023). Polymorphisms in ACE1, TMPRSS2, IFIH1, IFNAR2, and TYK2 Genes Are Associated with Worse Clinical Outcomes in COVID-19. Genes, 14.","DOI":"10.3390\/genes14010029"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1093\/hmg\/ddac158","article-title":"Detailed stratified GWAS analysis for severe COVID-19 in four European populations","volume":"31","author":"Degenhardt","year":"2022","journal-title":"Hum. Mol. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jinf.2020.11.031","article-title":"Mendelian randomization analysis identified genes pleiotropically associated with the risk and prognosis of COVID-19","volume":"82","author":"Liu","year":"2021","journal-title":"J. Infect."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41591-021-01310-z","article-title":"Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19","volume":"27","author":"Gaziano","year":"2021","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/hmg\/ddab125","article-title":"Integrative genomics analysis reveals a 21q22.11 locus contributing risk to COVID-19","volume":"30","author":"Ma","year":"2021","journal-title":"Hum. Mol. Genet."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"949413","DOI":"10.3389\/fimmu.2022.949413","article-title":"IFNAR2 relevance in the clinical outcome of individuals with severe COVID-19","volume":"13","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Nhung, V.P., Ton, N.D., Ngoc, T.T.B., Thuong, M.T.H., Hai, N.T.T., Oanh, K.T.P., Hien, L.T.T., Thach, P.N., Van Hai, N., and Ha, N.H. (2022). Host Genetic Risk Factors Associated with COVID-19 Susceptibility and Severity in Vietnamese. Genes, 13.","DOI":"10.3390\/genes13101884"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1002\/hep.22877","article-title":"Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial","volume":"49","author":"Welzel","year":"2009","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jgar.2021.06.005","article-title":"Loss-of-function mutations in IFNAR2 in COVID-19 severe infection susceptibility","volume":"26","author":"Smieszek","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10875-021-01166-5","article-title":"A Case of Autosomal Recessive Interferon Alpha\/Beta Receptor Alpha Chain (IFNAR1) Deficiency with Severe COVID-19","volume":"42","author":"Khanmohammadi","year":"2022","journal-title":"J. Clin. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"eabd4570","DOI":"10.1126\/science.abd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e20212427","DOI":"10.1084\/jem.20212427","article-title":"Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic","volume":"219","author":"Duncan","year":"2022","journal-title":"J. Exp. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13054-023-04388-8","article-title":"Polymorphism in interferon alpha\/beta receptor contributes to glucocorticoid response and outcome of ARDS and COVID-19","volume":"27","author":"Jalkanen","year":"2023","journal-title":"Crit. Care"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"859508","DOI":"10.3389\/fgene.2022.859508","article-title":"An Evolutionary Insight Into the Heterogeneous Severity Pattern of the SARS-CoV-2 Infection","volume":"13","author":"Raza","year":"2022","journal-title":"Front. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Pahl, M.C., Le Coz, C., Su, C., Sharma, P., Thomas, R.M., Pippin, J.A., Cabrera, E.C., Johnson, M.E., Leonard, M.E., and Lu, S. (2022). Implicating effector genes at COVID-19 GWAS loci using promoter-focused Capture-C in disease-relevant immune cell types. Genome Biol., 23.","DOI":"10.1186\/s13059-022-02691-1"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1073880","DOI":"10.3389\/fgene.2022.1073880","article-title":"Targeted screening of genetic associations with COVID-19 susceptibility and severity","volume":"13","author":"Li","year":"2022","journal-title":"Front. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41588-023-01375-1","article-title":"Single-cell analyses and host genetics highlight the role of innate immune cells in COVID-19 severity","volume":"55","author":"Edahiro","year":"2023","journal-title":"Nat. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"11173","DOI":"10.1080\/07391102.2021.1957714","article-title":"Deleterious single nucleotide polymorphisms (SNPs) of human IFNAR2 gene facilitate COVID-19 severity in patients: A comprehensive in silico approach","volume":"40","author":"Akter","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"307ra154","DOI":"10.1126\/scitranslmed.aac4227","article-title":"Human IFNAR2 deficiency: Lessons for antiviral immunity","volume":"7","author":"Duncan","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/jvh.12817","article-title":"Role of Functional IFNL4, IFNLR1, IFNA, IFNAR2 Polymorphisms in Hepatitis B virus-related liver disease in Han Chinese population","volume":"25","author":"Ma","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_48","unstructured":"He, X.-X., Chang, Y., Jiang, H.-J., Tang, F., Meng, F.-Y., Xie, Q.-H., Li, P.-Y., Song, Y.-H., Lin, J.-S., and Zou, R. (2023, September 06). Persistent Effect of IFNAR-1 Genetic Polymorphism on the Long-Term Pathogenesis of Chronic HBV Infection. Available online: www.liebertonline.com."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1365-2893.2009.01095.x","article-title":"Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients","volume":"16","author":"Wada","year":"2009","journal-title":"J. Viral Hepat."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired Type I Interferon Activity and Inflammatory Responses in Severe COVID-19 Patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1089\/jir.2014.0227","article-title":"Disease-promoting effects of type i interferons in viral, bacterial, and coinfections","volume":"35","author":"Davidson","year":"2015","journal-title":"J. Interf. Cytokine Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e20200653","DOI":"10.1084\/jem.20200653","article-title":"COVID-19 and emerging viral infections: The case for interferon lambda","volume":"217","author":"Alphonse","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_53","unstructured":"Hwang, S.Y., Hertzog, P.J., Holland, K.A., Sumarsono, S.H., Tymms, M.J., Hamilton, J.A., Whitty, G., Bertoncello, I., and Kola, I. (2023, September 12). A Null Mutation in the Gene Encoding a Type I Interferon Receptor Component Eliminates Antiproliferative and Antiviral Responses to Interferons a and f8 and Alters Macrophage Responses (Gene Targeting\/Viral Infection\/Macrophages\/Signal Transduction). Available online: https:\/\/www.pnas.org."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Langer, J.A. (2023, September 12). Interferon at 50: New Molecules, New Potential, New (and Old) Questions Downloaded from. Available online: www.stke.org\/cgi\/content\/full\/2007\/405\/pe53http:\/\/stke.sciencemag.org\/.","DOI":"10.1126\/stke.4052007pe53"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"104811","DOI":"10.1016\/j.antiviral.2020.104811","article-title":"Antiviral activities of type I interferons to SARS-CoV-2 infection","volume":"179","author":"Mantlo","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JVI.01410-20","article-title":"Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV","volume":"94","author":"Lokugamage","year":"2020","journal-title":"J. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/mBio.01928-20","article-title":"Antiviral activity of type i, ii, and iii interferons counterbalances ace2 inducibility and restricts SARS-CoV-2","volume":"11","author":"Busnadiego","year":"2020","journal-title":"Mbio"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JVI.00985-20","article-title":"Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures","volume":"94","author":"Vanderheiden","year":"2020","journal-title":"J. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e20220131","DOI":"10.1084\/jem.20220131","article-title":"Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia","volume":"219","author":"Zhang","year":"2022","journal-title":"J. Exp. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/jir.2010.0098","article-title":"Role of differential expression of interferon receptor isoforms on the response of multiple sclerosis patients to therapy with interferon beta","volume":"30","author":"Gilli","year":"2010","journal-title":"J. Interf. Cytokine Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"7554","DOI":"10.1074\/jbc.M116.773788","article-title":"A hot spot on interferon \u03b1\/\u03b2 receptor subunit 1 (IFNAR1) underpins its interaction with interferon-\u03b2 and dictates signaling","volume":"292","author":"Matthews","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Zoellner, N., Coesfeld, N., De Vos, F.H., Denter, J., Xu, H.C., Zimmer, E., Knebel, B., Al-Hasani, H., Mossner, S., and Lang, P.A. (2022). Synthetic mimetics assigned a major role to IFNAR2 in type I interferon signaling. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.947169"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/12\/11\/1320\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:18:02Z","timestamp":1760131082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/12\/11\/1320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":62,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["pathogens12111320"],"URL":"https:\/\/doi.org\/10.3390\/pathogens12111320","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,6]]}}}